BofA analyst Tazeen Ahmad lowered the firm’s price target on Denali Therapeutics (DNLI) to $26 from $27 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics: Promising Future with Tivi Approval and Unique Brain Shuttling Platform
- Denali Therapeutics: Strategic Positioning and Growth Potential with Pioneering TfR-Enabled Medicine Launch
- Denali Therapeutics Reports Increased Losses Amid Strategic Collaborations
- Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating
- Denali Therapeutics reports Q3 EPS (74c), consensus (76c)